Embolism
30
2
4
16
Key Insights
Highlights
Success Rate
94% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
3.3%
1 terminated out of 30 trials
94.1%
+7.6% vs benchmark
30%
9 trials in Phase 3/4
19%
3 of 16 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 16 completed trials
Clinical Trials (30)
Anticoagulation in Patients With Venous Thromboembolism and Cancer
Aventus Thrombectomy System Pulmonary Embolism Clinical Study
Safety and Efficiency of the YEARS Algorithm Versus Computed Tomography Pulmonary Angiography Alone for Suspected Pulmonary Embolism in Patients With Malignancy
SYMPHONY-PE Study for Treatment of Pulmonary Embolism
Clinical Surveillance vs. Anticoagulation for Low-risk Patients With Isolated Subsegmental Pulmonary Embolism
Arterial Embolism After Catheter Ablation of Atrial Fibrillation. ATRIAL FIBRILLATION
What is the Optimal Antithrombotic Strategy in Patients With Atrial Fibrillation Undergoing PCI?
Prediction of the Risks of Cardiovascular Mortality
Microembolic Detection in Acute Ischemic Stroke Patients With Atrial Fibrillation and Outcome
Protect the Head to Head Study
Blood Management During ECMO for Cardiac Support
Embolism in COVID-19 Positive Patients
Thrombembolism After Robot- Assisted Surgery in Urology
Evaluation of the Severity of Right to Left Shunt in PFO Patients After Systemic Embolism
Effect of a Novel Reamer-Irrigator-Aspirator on the Incidence of Fat Embolism
Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation
Use of the GARDEX™ Embolic Protection Device During Percutaneous Coronary Interventions of Saphenous Vein Graft
Influence of Diagnostic Errors on the Prognosis of Acute Pulmonary Embolism
Efficacy and Safety of Low-molecular Weight Heparin for Thromboprophylaxis in Acutely Ill Medical Patients
Non-interventional Local Study on Prescription Behavior of Anticoagulation Therapy in Secondary Stroke Prevention in Atrial Fibrillation Patients